Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
lung cancer
Biotech
OS' drug stopped lung cancer from returning in 3rd of patients
OS Therapies’ HER2-focused immunotherapy prevented patients’ lung cancer from returning in 33% of cases, hitting the primary goal of a phase 2 trial.
James Waldron
Jan 15, 2025 9:55am
Pfizer, Flagship return to obesity as part of 10-program collab
Nov 20, 2024 8:05am
FDA clears airway stent covered with human tissue
Oct 22, 2024 10:42am
FDA approves Novocure’s tumor field therapy for metastatic NSCLC
Oct 16, 2024 10:14am
Black Diamond, Ideaya mull registrational trials for cancer meds
Sep 23, 2024 12:18pm
Scorpion snaps up $150M series C to broaden clinical plans
Jul 16, 2024 9:40am